Research Topics
Species | William D TapSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanomaWilliam D Tap
Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
Neoplasia 12:637-49. 2010..We sought to investigate the efficacy of PLX4032 (BRAF inhibitor) to identify patterns/predictors of response/resistance and to study the effects of BRAF in melanoma...
Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridizationWilliam D Tap
Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
Genes Chromosomes Cancer 50:95-112. 2011..This detailed genetic mapping provides insight into the heterogeneity of WD and DDLS and the chromosomal and genetic abnormalities that are present in and distinguish these mesenchymal malignancies...
Targeted therapies for soft-tissue sarcomasWilliam D Tap
UCLA Sarcoma Program, Division of Hematology Oncology, Los Angeles, CA 90095 7059, USA
Expert Rev Anticancer Ther 7:725-33. 2007..This review will outline current areas of therapeutic interest in soft-tissue sarcomas with regard to agents that have reached clinical testing...- 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapyKen Herrmann
Division of Surgical Oncology, University of California at Los Angeles, 10833 Le Conte Avenue, Rm 54 140 CHS, Los Angeles, CA 90095, USA
Clin Cancer Res 18:2024-31. 2012..We prospectively evaluated whether 2[18F]fluoro-2-deoxy-d-glucose ((18)F-FDG)-PET/computed tomographic (CT) imaging after the initial cycle of neoadjuvant therapy could predict overall survival in these patients... - 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic responseMatthias R Benz
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1782, USA
Cancer 118:3135-44. 2012.... - Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benignMatthias R Benz
Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California 90095 1782, USA
Cancer 116:451-8. 2010..The aim of this study was to evaluate whether F18-fluorodeoxyglucose positron emission tomography (FDG PET) can differentiate malignant (MPNST) from benign PNSTs... - FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomasMatthias R Benz
Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 1782, USA
Clin Cancer Res 15:2856-63. 2009.... - Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcomaNicholas M Bernthal
Department of Orthopedics, UCLA Orthopedic Hospital, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California 90095 1782, USA
Cancer 118:5888-93. 2012..In addition, the value of pathologic necrosis induced by a single cycle of neoadjuvant chemotherapy was analyzed as a predictive marker of disease-free and overall survival... - FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone SarcomasMatthias R Benz
Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095 1782, USA
Sarcoma 2010:143540. 2010..Conclusion. These results suggest that changes in FDG-SUVmax at the end of neoadjuvant treatment can identify histopathologic responders and non-responders in adult primary bone sarcoma patients... - Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomasBartosz Chmielowski
Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, University of California Los Angeles, Santa Monica, CA 90404, USA
Expert Rev Anticancer Ther 12:1217-28. 2012.... - Utilization of positron emission tomography in the management of patients with sarcomaMatthias R Benz
Departments of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California 90095, USA
Curr Opin Oncol 21:345-51. 2009..In this review, the recent literature covering all aspects of PET imaging in the management of patients with soft tissue and bone sarcomas will be discussed... - Evaluation of neoadjuvant therapy and histopathologic response in primary, high-grade retroperitoneal sarcomas using the sarcoma nomogramTimothy R Donahue
Department of Surgery, Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, California 90095 1782, USA
Cancer 116:3883-91. 2010..Patients with primary high-grade retroperitoneal soft tissue sarcomas have a 5-year disease-specific survival (DSS) of <40%. The impact of neoadjuvant therapy on histopathologic response and DSS are unknown... - Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibitionKathleen B Smith
Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California 90095, USA
Am J Pathol 182:1400-11. 2013..These human xenograft models may facilitate liposarcoma research and accelerate the generation of readily translatable preclinical data that could ultimately influence patient care... - The multidisciplinary management of osteosarcomaNoah Federman
Division of Pediatric Hematology Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Curr Treat Options Oncol 10:82-93. 2009..The treatment of metastatic, recurrent and/or refractory disease is more controversial. Despite advances in systemic treatment, surgical technique, and supportive care, the overall outcome is still poor... - Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilitiesJennifer L Anderson
Molecular Biology Interdepartmental PhD Program, University of California, Los Angeles, USA
Pediatr Res 72:112-21. 2012..This review summarizes the molecular pathology of a subset of pediatric sarcomas with tumor-associated translocations and how increased understanding at the molecular level is being translated to novel therapeutic advances... - Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatmentDaniel Braas
Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California 90095, USA
Cancer Discov 2:1109-17. 2012..Thus, we suggest a new treatment paradigm for liposarcoma patients that uses [18F]-FAC-PET in the clinic to delineate gemcitabine responders from nonresponders... - Advances in chemotherapy for patients with extremity soft tissue sarcomaFritz C Eilber
University of California, Los Angeles, UCLA Medical Center, 90095 1782, USA
Orthop Clin North Am 37:15-22. 2006..Until a less toxic targeted systemic therapy is developed, treatment with ifosfamide should be strongly considered in patients who have high-risk primary extremity soft tissue sarcomas... - Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumorsWilliam D Tap
University of California, Los Angeles Medical Center, Los Angeles, CA, USA
J Clin Oncol 30:1849-56. 2012..An open-label phase II study was conducted to evaluate the efficacy and safety of ganitumab monotherapy in patients with metastatic Ewing family tumors (EFT) or desmoplastic small round cell tumors (DSRCT)... - Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomasVladimir Evilevitch
Abteilung Nuklearmedizin University of Freiburg, Freiburg, Germany
Clin Cancer Res 14:715-20. 2008..The aim of this study was to prospectively evaluate whether positron emission tomography with (18)F-fluorodeoxyglucose (FDG-PET) allows for a more accurate evaluation of histopathologic response...